Surfactant protein A differentially regulates peripheral and inflammatory neutrophil chemotaxis

Trista L. Schagat1, Jessica A. Wofford1, Kelly E. Greene2, and Jo Rae Wright1

1 Department of Cell Biology, Duke University Medical Center, Durham, North Carolina 27710; and 2 Department of Medicine, National Jewish Medical and Research Center, Denver, Colorado 80206


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Surfactant protein A (SP-A), a pulmonary lectin, plays an important role in regulating innate immune cell function. Besides accelerating pathogen clearance by pulmonary phagocytes, SP-A also stimulates alveolar macrophage chemotaxis and directed actin polymerization. We hypothesized that SP-A would also stimulate neutrophil chemotaxis. With the use of a Boyden chamber assay, we found that SP-A (0.5-25 µg/ml) did not stimulate chemotaxis of rat peripheral neutrophils or inflammatory bronchoalveolar lavage (BAL) neutrophils isolated from LPS-treated lungs. However, SP-A affected neutrophil chemotaxis toward the bacterial peptide formyl-met-leu-phe (fMLP). Surprisingly, the effect was different for the two neutrophil populations: SP-A reduced peripheral neutrophil chemotaxis toward fMLP (49 ± 5% fMLP alone) and enhanced inflammatory BAL neutrophil chemotaxis (277 ± 48% fMLP alone). This differential effect was not seen for the homologous proteins mannose binding lectin and complement protein 1q but was recapitulated by type IV collagen. SP-A bound both neutrophil populations comparably and did not alter formyl peptide binding. These data support a role for SP-A in regulating neutrophil migration in pulmonary tissue.

lung; formyl-met-leu-phe; collectin; inflammation


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

AT THE INITIATION of inflammation, neutrophils are recruited from the bloodstream into extravascular tissue. The presence of an inflammatory stimulus in the tissue, such as bacteria or bacterial LPS, results in the localized generation of cytokines, leukotrienes, and other proinflammatory mediators that enter the vasculature and stimulate the surrounding tissue, causing changes in surface molecule expression and potentiation of proinflammatory mediator production. Circulating neutrophils respond to these stimuli by altering surface molecule expression resulting in neutrophil adhesion to the surrounding vascular endothelium. Gradients of proinflammatory signals then stimulate the migration of these neutrophils across the vascular endothelium and into the adjacent infected tissue (reviewed in Refs. 20, 21).

The directed migration or chemotaxis of neutrophils is essential to execution of an inflammatory response. A variety of molecules are known to stimulate neutrophil chemotaxis (7). These include microbial products such as the bacterial peptide formyl met-leu-phe (fMLP), activated complement (C5a), cytokines such as IL-8 and macrophage inhibitory protein 2 (MIP-2), and bioactive lipids such as leukotriene B4. All of these chemoattractants bind G protein-coupled receptors on the surface of neutrophils. Ligand binding of these receptors stimulates signaling events that result in cytoskeletal rearrangements and cell migration.

Surfactant protein A (SP-A) is a large multimeric protein found in the airways and alveoli of the lungs. SP-A is a member of the collectin protein family that is characterized by NH2-terminal collagen-like domains and COOH-terminal lectin, or carbohydrate-binding domains. These proteins are innate immune molecules, and SP-A's best-characterized immunoregulatory interaction is with the resident pulmonary phagocyte, the alveolar macrophage (30). SP-A stimulates a variety of macrophage responses such as chemotaxis, actin polymerization, and phagocytosis (25, 30, 31). SP-A also regulates responses involved in the initiation and potentiation of inflammation by decreasing proinflammatory tumor necrosis factor-alpha production in response to LPS (14) and by accelerating the clearance of apoptotic neutrophils during the resolution of inflammation (17). In this way, SP-A is believed to help protect the delicate pulmonary tissue from potentially damaging effects of inflammation. Studies with mice made deficient for SP-A by homologous recombination support this hypothesis; these mice show a decreased ability to clear a pulmonary bacterial challenge and a large and persistent pulmonary infiltration of neutrophils (12).

In this study, we investigated the ability of SP-A to regulate neutrophil chemotaxis and found that although SP-A did not directly stimulate chemotaxis, it did regulate neutrophil chemotaxis toward known chemoattractants. This regulation was, however, dependent on the activation state of the neutrophil; peripheral neutrophils showed decreased chemotaxis in the presence of SP-A, and neutrophils isolated from inflamed lungs showed increased chemotaxis in the presence of SP-A. We examined the ability of homologous proteins to mediate neutrophil chemotaxis and explored the mechanism by which SP-A is differentially regulating the migration of the two different neutrophil populations. This study provides evidence that SP-A indeed regulates neutrophil migration most likely via its collagen-like domain through some internal regulatory mechanism that remains to be identified.


    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Reagents. Hetastarch was produced by Abbott Laboratories (North Chicago, IL). DPBS, Gey's balanced salt solution (GBSS), and HBSS were obtained from Gibco Laboratories (Grand Island, NY). Iodo-Beads, desalting gel columns, and bicinchoninic acid protein assays were all obtained from Pierce (Rockford, IL). Na125I was purchased from DuPont-NEN (Boston, MA). Human serum C1q was purchased from Advanced Research Technologies (San Diego, CA). IgG purified from normal rat serum was purchased from Sigma Chemical (St. Louis, MO). The IgG was reconstituted from lyophilized powder in saline and used without further treatment. All other chemicals used were from Sigma Chemical, unless otherwise indicated.

Animals. Male Sprague-Dawley rats weighing ~200-400 g were obtained from Charles River (Raleigh, NC) or Taconic Farms (Germantown, NY).

Protein purification. SP-A was purified from the bronchoalveolar lavage (BAL) fluid of patients with alveolar proteinosis as previously described (14). Briefly, SP-A was extracted from lavage fluid with butanol and sequential solubilization in octylglucoside and 5 mM Tris, pH 7.4. The SP-A was treated with polymyxin B agarose beads to reduce endotoxin contamination. All SP-A preparations had <0.1 pg endotoxin/µg SP-A by the Limulus amebocyte lysate assay QCL-1000 (BioWhittaker, Walkersville, MD). SP-A was stored in 5 mM Tris, pH 7.4, at -20°C. Heat treatment of SP-A was carried out at 95°C for 10 min.

Mannose binding lectin (MBL) was purified from rat serum (Pel-Freeze, Rogers, AR) by affinity and gel filtration chromatography as previously described (24).

Iodination of SP-A. Purified SP-A was iodinated using N-chloro-benzenesulfonamide oxidizing agent immobilized on Pierce Iodo-Beads (26). Free Na125I was separated from 125I-labeled protein on D-salt exocellulose GF-5 desalting gel columns. Fractions that contained radioactivity that was >85% precipitable by trichloroacetic acid were analyzed for protein concentrations by bicinchoninic acid protein assay and stored at 4°C. Radiolabeled SP-A was used within 2 wk.

Neutrophil isolation. Peripheral neutrophils were isolated as previously described with minor modifications (23, 29). Briefly, rats were anesthetized by intramuscular injection of 0.1 mg acepromazine, 7 mg ketamine, and 29 mg xylazine per 250 g body wt, and the jugular was cannulated with a 23-gauge butterfly needle attached to a three-way stop cock. An exchange of 3-4 ml of 6% hetastarch solution with 100 U/ml heparin for 3-4 ml of blood was performed until 40 ml were exchanged per rat. The first 10 ml of blood were collected in a syringe containing 10 ml of the hetastarch solution. After the exchange, blood was collected until the rats died. Blood was allowed to settle 30-45 min at room temperature, and the red blood cell-depleted fraction was collected and centrifuged at 330 g for 10 min. Cells were resuspended in 2 ml of DPBS and underlayed with a five-step Percoll gradient. Step densities were 1.081, 1.085, 1.089, 1.093, and 1.097. Gradients were centrifuged at 500 g for 30 min at room temperature, and the fractions at the interfaces of 1.085-1.089 and 1.089-1.093 density layers were pooled, washed, and resuspended in the appropriate buffer. Neutrophil purities were 83 ± 3% as determined by hematoxylin differential stain (EM Science, Gibbstown, NJ). Other cell types present were 7 ± 1% eosinophils and 10 ± 3% mononuclear cells. Cells were 98 ± 1% viable as determined by trypan blue exclusion.

For isolation of inflammatory BAL neutrophils, rats received an intratracheal instillation of LPS (100 µg of O26:B6/kg rat in 350 µl of normal saline). Twelve hours later, the lungs were lavaged six times with PBS (pH 7.2) containing 0.2 mM EGTA. Cells were collected by centrifuging the BAL fluid for 10 min at 228 g. Cells were then suspended in 2 ml of DPBS per rat and underlayed with the same five-step Percoll gradient used for isolation of peripheral neutrophils. Gradients were centrifuged at 500 g for 30 min at room temperature, and the fractions at the interfaces of 1.085-1.089 and 1.089-1.093 density layers were pooled, washed, and resuspended in the appropriate buffer. Neutrophil purities were >97% as determined by hematoxylin differential stain.

Human peripheral neutrophils were isolated from whole blood using Mono-Poly Resolving Medium (ICN Biochemicals, Aurora, OH) according to the manufacturer's specifications. Neutrophils were >95% pure.

Chemotaxis assay. Chemotaxis assays were performed using a Neuro Probe 48-well microchemotaxis chamber (Cabin John, MD) (31). Lower wells were filled with the chemotactic test solution diluted in chemotaxis buffer (GBSS + 2% BSA). Poretics polyvinylpyrrolidone-free polycarbonate filters with 2-µm pores (Osmonics, Livermore, CA) were used. The assembly was incubated at 37°C, 5% CO2 for 10 min before cell suspensions (2.5 × 106 cells/ml chemotaxis buffer) were added. After a 30-min incubation at 37°C, 5% CO2, the filter was stained by hematoxylin differential stain and analyzed by light microscopy for the number of cells that had migrated through the filter. Ten randomly selected oil immersion fields were counted at ×100 magnification. Chemotactic stimuli were analyzed in triplicate and averaged for each experiment.

Phagocytosis assay. Fluorescein beads were conjugated with BSA according to the manufacturer's directions in the Polysciences Carbodiimide kit (Warrington, PA). Neutrophils at 106 cells/ml were coincubated 1:10 with BSA-coupled beads in a final assay volume of 0.5 ml PBS + 0.1% BSA. Incubations were carried out in BSA-coated tubes (coated for 1 h at 37°C) for 30 min at 37°C in the presence and absence of 25 µg/ml SP-A. Cells were then washed three times and fixed with 1% formaldehyde before analysis by flow cytometry.

Iodinated SP-A binding assay. To measure binding of iodinated SP-A, neutrophils were suspended at 5 × 106 cells/ml in binding buffer (DPBS with 0.1% BSA and either 0.9 mM CaCl2 + 0.5 mM MgCl2 or 1 mM EDTA as indicated). Assay tubes were precoated with 1% BSA overnight at 4°C. Iodinated SP-A was coincubated with 2 × 106 cells in 0.5 ml of buffer for 4 h at 4°C with gentle rotation. To minimize nonspecific absorption of radioactivity to the tubes, cells were washed once with cold binding buffer lacking BSA and transferred to new tubes. Cells were then washed twice more and lysed (50 mM sodium phosphate buffer, pH 7.2, 150 mM NaCl, 2 mM EDTA, and 0.5% Nonidet P-40). All washes were done at 4°C. Incorporated radioactivity was analyzed by gamma counting, and radioactive signal was normalized to total cellular protein recovered (quantitated by bicinchoninic acid protein assay). Background was determined by performing the assay in the absence of cells and detectable background counts were subtracted from the samples with cells.

Quantitation of fMLP receptor expression. fMLP receptor expression was measured using the fluorescein-conjugated formyl peptide formyl-Nle-Leu-Phe-Nle-Tyr-Lys (Molecular Probes, Eugene, OR) (1). Varying concentrations of peptide (1, 2, 5, 10, and 20 nM) were incubated with 2.5 × 106 neutrophils/ml binding buffer (HBSS + 1% BSA + 0.1% azide) for 30 min on ice. Cells were then washed and resuspended in fixative (1% formaldehyde in DPBS) for analysis by flow cytometry. Cells were analyzed for the mean relative fluorescence as an indication of the relative quantity of formyl peptide bound. For measurement of the effect of SP-A on formyl peptide binding, 25 µg/ml SP-A were added to the binding reaction. For measurement of the effect of SP-A on fMLP receptor expression, cells were incubated in the chemotaxis buffer plus 25 µg/ml SP-A for 30 min at 37°C with gentle shaking. Cells were then washed with DPBS without calcium or magnesium + 1 mM EDTA + 1% BSA and resuspended in binding buffer, and formyl peptide binding was measured as described.

CD11b expression. Neutrophils at 2 × 106 cells/ml HBSS + 0.1% BSA were incubated with FITC-conjugated CD11b (PharMingen, San Diego, CA) for 5 min at 37°C and then stimulated with SP-A (25 µg/ml), fMLP (0.1 mM), or SP-A + fMLP for 10 min at 37°C (3). Cells were immediately washed with 1 ml of cold HBSS + 0.1% BSA and suspended in fixative for analysis by flow cytometry.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

SP-A does not directly stimulate neutrophil chemotaxis. In contrast to its effects on macrophage chemotaxis, SP-A did not directly stimulate peripheral or inflammatory BAL neutrophil migration above buffer alone (GBSS) at a range of concentrations tested (0.5-25 µg/ml) (Fig. 1). The bacterial peptide fMLP (10 nM) stimulated chemotaxis, and inflammatory BAL neutrophils were significantly more responsive to fMLP than peripheral neutrophils.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 1.   Effect of surfactant protein A (SP-A) on neutrophil chemotaxis. Rat peripheral and inflammatory bronchoalveolar lavage (BAL) neutrophils were allowed to migrate through a membrane with 2-µm pores toward buffer control [Gey's balanced salt solution (GBSS)], SP-A (0.5, 2, or 25 µg/ml), or formyl-met-leu-phe (fMLP; 10 nM) for 30 min. Membranes were then stained and scored for the average number of neutrophils that had migrated through the membrane per oil immersion field (OIF). Experiments were done in triplicate. Means ± SE; n = 3-10. * P < 0.005 vs. GBSS.

SP-A regulates neutrophil chemotaxis stimulated by chemoattractants. Although SP-A alone did not directly stimulate neutrophil migration, we analyzed its ability to affect neutrophil migration toward several different chemoattractants. We measured the effect of 25 µg/ml SP-A on neutrophil chemotaxis toward MIP-2, activated complement protein C3b in zymosan-activated serum (ZAS), and fMLP. SP-A significantly altered both peripheral and inflammatory BAL chemotaxis toward these chemoattractants. However, the effect was dependent on the activation state of the neutrophil. SP-A significantly inhibited peripheral neutrophil chemotaxis toward MIP-2 and fMLP and significantly enhanced inflammatory BAL chemotaxis toward each chemoattractant tested (Fig. 2). Significant inhibition of peripheral neutrophil chemotaxis toward ZAS was not observed at the concentration tested (5% ZAS) (Fig. 2).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of SP-A on neutrophil chemotaxis toward different chemoattractants. Chemotaxis of rat peripheral and inflammatory BAL neutrophils toward buffer control (GBSS), macrophage inhibitory protein 2 (MIP-2; 50 ng/ml), zymosan-activated serum (ZAS; 5%), or fMLP (10 nM) in the absence and presence of SP-A (25 µg/ml) was measured for 30 min. Experiments were done in triplicate. Relative neutrophil chemotaxis = [(chemotaxis toward chemoattractant or control + SP-A)/(chemotaxis toward chemoattractant or control alone) × 100]. Means ± SE; n = 4-8. * P <=  0.006 vs. BAL neutrophil chemotaxis toward chemoattractant alone. dagger  P <=  0.006 vs. peripheral neutrophil chemotaxis toward chemoattractant alone.

To further substantiate these observations and because human SP-A was used in these experiments with rat cells, we tested SP-A's effect on human peripheral neutrophil migration toward IL-8. As observed with rat peripheral neutrophil chemotaxis toward fMLP and MIP-2, human peripheral neutrophil chemotaxis toward IL-8 was significantly reduced in the presence of 25 µg/ml SP-A (Fig. 3).


View larger version (9K):
[in this window]
[in a new window]
 
Fig. 3.   Effect of SP-A on human peripheral neutrophil chemotaxis. Chemotaxis of human peripheral neutrophils toward SP-A (25 µg/ml), IL-8 (1 nM), and SP-A + IL-8 was measured for 30 min and compared with neutrophil migration toward buffer alone. Experiments were done in triplicate. Data are expressed as % chemotaxis of migration toward buffer alone. Means ± SE; n = 3. * P < 0.04 vs. buffer. dagger  P = 0.03 vs. IL-8.

To assess whether SP-A's ability to regulate neutrophil chemotaxis was dose dependent, we examined the effect of a range of SP-A doses on neutrophil chemotaxis toward fMLP. SP-A at 25 and 50 µg/ml significantly altered both peripheral and inflammatory BAL neutrophil chemotaxis toward 10 nM fMLP (Fig. 4). In the presence of 25 µg/ml SP-A, inflammatory BAL neutrophil chemotaxis toward fMLP was 185 ± 41% chemotaxis toward fMLP alone, whereas peripheral neutrophil chemotaxis toward fMLP was reduced to 66 ± 8% in the presence of SP-A.


View larger version (14K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of SP-A dose on neutrophil chemotaxis toward fMLP. Chemotaxis of peripheral and inflammatory BAL neutrophils toward 10 nM fMLP was measured in the presence of 0, 2, 10, 25, and 50 µg/ml SP-A for 30 min. Experiments were done in triplicate. Relative neutrophil chemotaxis = [(chemotaxis toward fMLP + SP-A)/(chemotaxis toward fMLP alone) × 100]. Means ± SE. BAL: n = 5; peripheral: 0 and 25 µg/ml, n = 7; and 2, 10, and 50 µg/ml, n = 3. * P < 0.005 vs. BAL neutrophil chemotaxis toward fMLP alone. dagger  P < 0.005 vs. peripheral neutrophil chemotaxis toward fMLP alone.

BAL neutrophils were exposed to LPS in vivo before isolation. Because LPS is such a potent stimulus for neutrophils, it seemed possible that LPS exposure was responsible for the difference in functional responsiveness between the peripheral and BAL neutrophils. To test this theory, peripheral neutrophils were incubated in the presence of 100 ng/ml LPS (LCD 25, List Biologics) for 1 h at 37°C, 5% CO2. Cells were then assayed for their chemotactic responsiveness to 10 nM fMLP in the presence and absence of 25 µg/ml SP-A. Cells pretreated with LPS exhibited a stronger chemotactic response to fMLP (147 and 163% chemotaxis toward fMLP vs. untreated control, data from two independent experiments). However, SP-A inhibited chemotaxis of the LPS-treated peripheral neutrophils to a similar extent as the untreated peripheral neutrophils (63 and 54% and 67 and 33%, respectively, data from two independent experiments).

SP-A regulates neutrophil phagocytosis. To explore whether SP-A may regulate another aspect of neutrophil function, neutrophil phagocytosis was examined. Peripheral and inflammatory BAL neutrophils were incubated with BSA-conjugated fluorescein beads in the presence and absence of 25 µg/ml SP-A. SP-A significantly reduced peripheral neutrophil phagocytosis to 70 ± 9% vs. control, whereas SP-A enhanced BAL neutrophil phagocytosis to 143 ± 35% vs. control (Fig. 5). Although enhancement of BAL neutrophil phagocytosis was not statistically significant, SP-A clearly had different effects on peripheral and BAL neutrophils.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 5.   SP-A regulates neutrophil phagocytosis. Peripheral and inflammatory neutrophils were incubated 1:10 with fluorescein beads for 30 min in the absence and presence of 25 µg/ml SP-A. Cells were then washed, fixed, and analyzed by flow cytometery. Relative phagocytosis = (% neutrophil phagocytosis + SP-A)/(% neutrophil phagocytosis in the absence of SP-A). Means ± SE; n = 3-5. * P < 0.005 vs. phagocytosis in the absence of SP-A.

Specificity of SP-A's effect on neutrophil chemotaxis. To determine if SP-A's effect was specific, we examined the ability of other proteins to regulate neutrophil migration toward fMLP. IgG, which does not share any structural homology to SP-A but is a soluble immunoregulatory protein, did not alter peripheral or inflammatory BAL neutrophil chemotaxis toward fMLP (Table 1). MBL, a serum member of the collectin protein family, and complement protein C1q both share significant structural homology to SP-A. In contrast to SP-A, neither MBL nor C1q (at 25 µg/ml) significantly altered peripheral or inflammatory BAL neutrophil chemotaxis toward fMLP (Table 1). None of these proteins alone at 25 µg/ml significantly stimulated neutrophil chemotaxis (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table 1.   Effect of immune proteins on neutrophil chemotaxis toward fMLP

Because the collagen-like domain of SP-A is similar to type IV collagen, the ability of type IV collagen to regulate neutrophil migration toward fMLP was examined. Surprisingly, collagen had the same effect as SP-A: it inhibited peripheral neutrophil chemotaxis and enhanced inflammatory BAL neutrophil chemotaxis toward fMLP (Table 2). Also, similar to SP-A, collagen alone did not stimulate chemotaxis (data not shown). To determine if the collagen domain of SP-A was responsible for its regulation of neutrophil chemotaxis, we examined the effect of heat treatment on SP-A's function. Heat treatment abrogated the ability of collagen and SP-A to regulate peripheral and inflammatory BAL neutrophil chemotaxis (Table 2).

                              
View this table:
[in this window]
[in a new window]
 
Table 2.   Role of collagen in neutrophil chemotaxis toward fMLP

Binding of SP-A to peripheral vs. inflammatory BAL neutrophils. Because of the differential effect of SP-A on peripheral and inflammatory BAL neutrophil chemotaxis, we examined if there was a difference in binding of SP-A to the two neutrophil populations. Iodinated SP-A at 2, 5, and 10 µg/ml was incubated with the neutrophils for 4 h at 4°C. There was no apparent difference in binding of SP-A to peripheral and inflammatory BAL neutrophils (Fig. 6). Higher doses of SP-A were tested, but background levels of radioactivity (as assessed by radioactivity that pelleted in the absence of cells) became significant, suggesting that the iodinated protein was aggregating at concentrations equal to or greater than 25 µg/ml (data not shown).


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 6.   SP-A binding to neutrophils. Iodinated SP-A (2, 5, 10 µg/ml) was incubated with peripheral and inflammatory BAL neutrophils for 4 h at 4°C. This incubation was carried out either in the presence of 0.9 mM CaCl2 + 0.5 mM MgCl2 (A) or in the presence of 1 mM EDTA (B). Cells were then washed, and the amount of radioactivity associated with the cells was determined and normalized to the total protein recovered. Data are expressed as ng SP-A recovered/µg total protein recovered. Means ± SE; n = 3-4.

The calcium dependence of SP-A binding to neutrophils was also examined by measuring binding in the absence of calcium and the presence of 1 mM EDTA (Fig. 6B). Although SP-A binding was slightly reduced in the absence of calcium (more so in peripheral than in BAL neutrophils), there was no significant difference in the binding between the peripheral and inflammatory BAL neutrophils in the absence of calcium.

Effect of SP-A on fMLP receptor expression. To determine if SP-A's ability to regulate neutrophil chemotaxis is due to an alteration in fMLP receptor expression, we measured receptor expression on the peripheral vs. inflammatory BAL neutrophils. Fluorescein-conjugated formyl peptide (formyl-Nle-Leu-Phe-Nle-Tyr-Lys) at 1, 2, 5, 10, and 20 nM was incubated with peripheral and inflammatory BAL neutrophils for 30 min on ice. Formyl peptide binding to neutrophils was dose dependent and saturated between 5 and 10 nM (Fig. 7). As has been reported for LPS-stimulated peripheral neutrophils (1), we found that fMLP receptor expression was greater for activated inflammatory BAL neutrophils than for peripheral neutrophils (Fig. 7). To determine if the presence of SP-A could alter peptide binding or receptor expression, we added SP-A to the binding reaction or pretreated the neutrophils with SP-A under the chemotaxis assay conditions (30 min at 37°C). Neither coincubation of the peptide with SP-A (Fig. 7) nor pretreatment of the neutrophils with SP-A (data not shown) altered formyl peptide binding to the peripheral or inflammatory BAL neutrophils.


View larger version (21K):
[in this window]
[in a new window]
 
Fig. 7.   Formylated peptide binding to neutrophils. Fluorescein-conjugated formylated peptide (0, 1, 2, 5, 10, and 20 nM) was incubated with peripheral and inflammatory BAL neutrophils for 30 min on ice in the absence or presence of 25 µg/ml SP-A. Cells were then washed and analyzed by flow cytometry. Data are expressed as the mean relative fluorescence of the labeled peptide that bound to the cells. Means ± SE; n = 3.

Effect of SP-A on fMLP-stimulated CD11b levels. Besides stimulating chemotaxis, fMLP also upregulates CD11b expression on the neutrophil surface by stimulating release of secondary and tertiary granules and secretory vesicles where this beta 2-integrin is stored (4, 10). Consistent with the literature, we found that fMLP stimulated a significant increase in CD11b on the surface of peripheral neutrophils (Fig. 8). This was also observed for inflammatory BAL neutrophils, although the percent increase in levels was less in the BAL neutrophils than in the peripheral neutrophils (Fig. 8). This is likely due to the already high basal CD11b levels on the inflammatory BAL neutrophils (Fig. 8A). SP-A alone had no effect on levels of CD11b. However, SP-A subtly, yet significantly, reduced fMLP-stimulated CD11b levels in the peripheral neutrophils (Fig. 8B). SP-A had no significant effect on fMLP-stimulated CD11b expression on inflammatory BAL neutrophils.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   Effect of fMLP and SP-A on neutrophil CD11b expression. A: comparison of CD11b expression between peripheral and BAL neutrophils, either untreated (none) or treated with 10 nM fMLP. CD11b expression was detected by measuring FITC-anti-CD11b mAb binding. Data were collected by flow cytometry and expressed as mean relative fluorescence units (RFUs). B: relative effect of fMLP and SP-A treatment on neutrophil CD11b expression. Cells were incubated for 10 min before fixing at 37°C in the absence or presence of 25 µg/ml SP-A and/or 0.1 mM FMLP. Data are expressed as a percentage of fMLP-stimulated CD11b expression for each neutrophil population. Means ± SE; n = 4-5. * P < 0.005.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

These studies describe for the first time SP-A's ability to alter neutrophil responsiveness to chemoattractants. We show that SP-A enhances chemotaxis of inflammatory BAL neutrophils toward fMLP, MIP-2, and ZAS, and SP-A reduces peripheral neutrophil chemotaxis toward fMLP and MIP-2. Because of the inherent limitations of in vitro chemotaxis assays (reviewed in Ref. 28), we also investigated the effects of SP-A on other neutrophil functions, including phagocytosis and expression of CD11b. Although the effects of SP-A were more pronounced for chemotaxis than for other functions, we found that SP-A differentially regulates a variety of peripheral and inflammatory neutrophil functions. These studies suggest that SP-A may play an important role in regulating neutrophil functions in the lung. It was surprising that SP-A did not directly stimulate neutrophil chemotaxis, as has been observed by alveolar macrophages. A comparison of SP-A binding to alveolar macrophages vs. neutrophils (Fig. 6) suggests that neutrophils have one-fifth the number of SP-A binding sites as has been reported for alveolar macrophages (15). This suggests that neutrophils may lack a receptor for SP-A chemotactic stimulation. One study reported the ability of SP-A to stimulate peripheral neutrophil chemotaxis (6). The ability of SP-A to stimulate in their assays may be due to subtle assay differences or differences in SP-A preparations. To rule out the possibility of the lack of effect being due to the species discrepancy between the SP-A and cells used, we also examined whether human SP-A could stimulate human peripheral neutrophil chemotaxis. No chemotaxis was observed at 5 µg/ml (data not shown) or 25 µg/ml SP-A (Fig. 3). The inability of SP-A to directly stimulate chemotaxis is supported by a study that reports that exogenous surfactant is unable to stimulate neutrophil chemotaxis (8). Importantly, it should be noted that the BAL neutrophils have been previously exposed to SP-A. Thus, any regulatory effects or the lack thereof that are a consequence of this exposure cannot be controlled for.

The finding that SP-A differentially regulates peripheral and inflammatory BAL neutrophil chemotaxis toward fMLP, MIP-2, and ZAS is consistent with previous reports that exudated cells differ in many respects from peripheral blood cells (5, 16, 18, 27). The findings are also consistent with previous reports that SP-A has differential effects on activated vs. resting macrophages (9, 22). Neutrophils are rarely found in the alveolar space of the noninflamed lung, but when neutrophils are recruited during inflammation, migration into the alveolar space and in contact with SP-A would give them the capacity to respond more rapidly to chemoattractants that are present during inflammation. A role for SP-A in regulating neutrophil migration is supported by data obtained from studies with SP-A knockout mice, which show that once pulmonary inflammation is initiated, there is a large persistent infiltration of neutrophils into the pulmonary space (12) in the lungs of the knockout mice. However, it is important to note that the increased neutrophil migration in these models may be due to factors other than the absence of SP-A, including differences in cytokine levels and regulation of production of oxidant species.

Extracellular matrix proteins have been reported to affect leukocyte trafficking. Fibrin degradation products have been implicated in stimulating neutrophil chemotaxis, and chemotaxis was enhanced by the presence of LPS (11). Also, collagen has been reported to stimulate neutrophil chemotaxis (19). However, it has been reported that extracellular matrix produced by cultured endothelial cells has no neutrophil chemotactic activity yet did inhibit neutrophil activation by fMLP (13).

It does not seem likely that SP-A is altering chemoattractant interactions at the neutrophil plasma membrane. FITC-formyl peptide Nle-Leu-Phe-Nle-Tyr-Lys is a marker for fMLP receptors (1), and the presence of SP-A did not affect peptide binding (Fig. 7). Also, when neutrophils were pretreated with SP-A under chemotaxis assay conditions and receptor expression was examined, there was no difference in peptide binding (data not shown). All of the attractants tested stimulate neutrophils through G protein-coupled receptors. A phenomenon of these receptors is desensitization. During desensitization, after the ligand binds the receptor, the receptor is internalized, which leads to a reduced ability of the cells to respond to subsequent chemoattractant stimulation (reviewed in Ref. 2). An exciting possible implication of the data reported here is that SP-A may be altering this desensitization process. Future studies may determine if this is the case.

Overall, these studies add to the growing body of data describing SP-A's immunoregulatory role in the pulmonary tissue. These data show that this regulation is not only dependent on the type of leukocyte examined but also the activation state of the leukocyte. The ability of SP-A to differentially regulate different leukocyte populations supports the model that SP-A plays a significant role in tipping the balance of inflammation in favor of the beneficial vs. the damaging effects. In this way, SP-A is helping protect the delicate pulmonary epithelium while facilitating pathogen clearance.


    ACKNOWLEDGEMENTS

We thank H. Garner and P. Keating for purifying the SP-A used in these studies. We also thank Dr. T. R. Martin, University of Washington, Seattle, Washington, for helpful discussions and encouragement.


    FOOTNOTES

This work was supported by National Heart, Lung, and Blood Institute Grant RO1-HL-51134.

Address for reprint requests and other correspondence: J. R. Wright, Box 3709, Duke Univ. Medical Center, Durham, NC 27710 (E-mail: j.wright{at}cellbio.duke.edu).

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

August 30, 2002;10.1152/ajplung.00125.2002

Received 26 April 2002; accepted in final form 27 August 2002.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1.   Allen, C, Broom M, and Chadwick VS. Flow cytometry analysis of the expression of neutrophil. J Immunol Methods 149: 159-164, 1992[ISI][Medline].

2.   Ben-Baruch, A, Michiel DF, and Oppenheim JJ. Signals and receptors involved in recruitment of inflammatory cells. J Biol Chem 270: 11703-11706, 1995[Free Full Text].

3.   Betsuyaku, T, Liu F, Senior RM, Haug JS, Brown EJ, Jones SL, Matsushima K, and Link DC. A functional granulocyte colony-stimulating factor receptor is required for normal chemoattractant-induced neutrophil activation. J Clin Invest 103: 825-832, 1999[Abstract/Free Full Text].

4.   Borregaard, N, Christensen L, Bejerrum OW, Birgens HS, and Clemmensen I. Identification of a highly mobilizable subset of human neutrophil intracellular vesicles that contains tetranectin and latent alkaline phosphatase. J Clin Invest 85: 408-416, 1990[ISI][Medline].

5.   Condliffe, AM, Kitchen E, and Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Colch) 94: 461-471, 1998[ISI][Medline].

6.   Crouch, EC, Persson A, Griffin GL, Chang D, and Senior RM. Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes. Am J Respir Cell Mol Biol 12: 410-415, 1995[Abstract].

7.   Doherty, DE, Downey GP, Schwab BR, Elson E, and Worthen GS. Lipolysaccharide-induced monocyte retention in the lung. Role of monocyte stiffness, actin assembly, and CD18-dependent adherence. J Immunol 153: 241-255, 1994[Abstract/Free Full Text].

8.   Finck, CM, Hodell MG, Marx WH, Paskanik AM, McGraw DJ, Lutz CJ, Gatto LA, Picone AL, and Nieman GF. Endotoxin-stimulated alveolar macrophage recruitment of neutrophils and modulation with exogenous surfactant. Crit Care Med 26: 1414-1418, 1998[ISI][Medline].

9.   Hickman-Davis, J, Gibbs-Erwin J, Lindsey JR, and Matalon S. Surfactant protein A mediates mycoplasmacidal activity of alveolar macrophages by production of peroxynitrite. Proc Natl Acad Sci USA 96: 4953-4958, 1999[Abstract/Free Full Text].

10.   Jones, DH, Schmalstieg FC, Dempsey K, Krater SS, Nannen DD, Smith CW, and Anderson DC. Subcellular distribution and mobilization of MAC-1 (CD11b/CD18) in neonatal neutrophils. Blood 75: 488-498, 1990[Abstract].

11.   Leavell, KJ, Peterson MW, and Gross TJ. The role of fibrin degradation products in neutrophil recruitment to the lung. Am J Respir Cell Mol Biol 14: 53-60, 1996[Abstract].

12.   LeVine, AM, Whitsett JA, Gwozdz J, Richardson TR, Fisher JH, Burhans MS, and Korfhagen TR. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 165: 3934-3940, 2000[Abstract/Free Full Text].

13.   Matzner, Y, Vlodavsky I, Michaeli RI, and Eldor A. Selective inhibition of neutrophil activation by the subendothelial extracellular matrix: possible role in protection of the vessel wall during diapedesis. Exp Cell Res 189: 233-240, 1990[ISI][Medline].

14.   McIntosh, JC, Mervin-Blake S, Conner E, and Wright JR. Surfactant protein A protects growing cells and reduces TNF-alpha activity from LPS-stimulated macrophages. Am J Physiol Lung Cell Mol Physiol 271: L310-L319, 1996[Abstract/Free Full Text].

15.   Pison, U, Wright JR, and Hawgood S. Specific binding of surfactant protein SP-A to rat alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 262: L412-L417, 1992[Abstract/Free Full Text].

16.   Sato, S, Ouellet N, Pelletier I, Simard M, Rancourt A, and Bergeron MG. Role of galectin-3 as an adhesion molecule for neutrophil extravasation during streptococcal pneumonia. J Immunol 168: 1813-1822, 2002[Abstract/Free Full Text].

17.   Schagat, TL, Wofford JA, and Wright JR. Surfactant protein A enhances alveolar macrophage phagocytosis of apoptotic neutrophils. J Immunol 166: 2727-2733, 2001[Abstract/Free Full Text].

18.   Sengelov, H, Follin P, Kjeldsen L, Lollike K, Dahlgren C, and Borregaard N. Mobilization of granules and secretory vesicles during in vivo exudation of human neutrophils. J Immunol 154: 4157-4165, 1995[Abstract/Free Full Text].

19.   Senior, RM, Hinek A, Griffin GL, Pipoly DJ, and Crouch EC. Neutrophils show chemotaxis to type IV collagen and its 7S domain and contain a 67 kD type IV collagen binding protein with lectin properties. Am J Respir Cell Mol Biol 1: 479-487, 1989[ISI][Medline].

20.   Sibille, Y, and Marchandise FX. Pulmonary immune cells in health and disease: polymorphonuclear neutrophils. Eur Respir J 6: 1529-1543, 1993[Abstract].

21.   Sibille, Y, and Reynolds HY. Macrophages and polymorphonuclear neutrophils in lung defense and injury. Am Rev Respir Dis 141: 471-501, 1990[ISI][Medline].

22.   Stamme, C, Walsh E, and Wright JR. Surfactant protein A differentially regulates IFN-gamma - and LPS-induced nitrite production by rat alveolar macrophages. Am J Respir Cell Mol Biol 23: 772-779, 2000[Abstract/Free Full Text].

23.   Sugawara, T, Miyamoto M, Takayama S, and Kato M. Separation of neutrophils from blood in human and laboratory animals and comparison of the chemotaxis. J Pharmacol Toxicol Methods 33: 91-100, 1995[ISI][Medline].

24.   Tino, MJ, and Wright JR. Glycoprotein-340 binds surfactant protein-A (SP-A) and stimulates alveolar macrophage migration in an SP-A-independent manner. Am J Respir Cell Mol Biol 20: 759-768, 1999[Abstract/Free Full Text].

25.   Tino, MJ, and Wright JR. Surfactant protein A stimulates actin polymerization in alveolar macrophages but not peripheral blood monocytes (Abstract). Am J Respir Crit Care Med 153: A663, 1996.

26.   Tino, MJ, and Wright JR. Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 270: L677-L688, 1996[Abstract/Free Full Text].

27.   Wheeler, MA, Smith SD, Garcia-Cardena G, Nathan CF, Weiss RM, and Sessa WC. Bacterial infection induces nitric oxide synthase in human neutrophils. J Clin Invest 99: 110-116, 1997[Abstract/Free Full Text].

28.   Wilkinson, PC. Assays of leukocyte locomotion and chemotaxis. J Immunol Methods 216: 139-153, 1998[ISI][Medline].

29.   Williams, JH, Moser KM, Ulich T, and Cairo MS. Harvesting of noncirculating pool of polymorphonuclear leukocytes in rats by hetastartch exchange transfusion (HET): yield and functional assessment. J Leukoc Biol 42: 455-462, 1987[Abstract].

30.   Wright, JR. Immunomodulatory functions of surfactant. Physiol Rev 77: 931-962, 1997[Abstract/Free Full Text].

31.   Wright, JR, and Youmans DC. Pulmonary surfactant protein-A stimulates chemotaxis of alveolar macrophage. Am J Physiol Lung Cell Mol Physiol 264: L338-L344, 1993[Abstract/Free Full Text].


Am J Physiol Lung Cell Mol Physiol 284(1):L140-L147
1040-0605/03 $5.00 Copyright © 2003 the American Physiological Society